About Cranebio
Cranebio is a Healthcare company based in Minato (Japan) founded in 2021. Self-service genetic test kits for womens health are developed. Cranebio has raised $1.67 million across 1 funding round from investors including Axil Capital, Nippon Venture Capital and Akigin Capital Partners. Its chief executive, as recorded, is Daisuke Yamamoto. Its focus areas include HealthTech, Healthcare Booking Platforms, Diagnostics and Internet First Clinical Labs. Its competitors include Miltel and MyCode; 1 of its 2 listed competitors has raised funding.
Company details
Cranebio was founded in 2021 and is based in Minato, Japan. Operations focus on the biotechnology sector, where self-service genetic test kits for womens health are developed. A wearable testing device and a next-generation rapid kit utilizing DNA origami technology are offered to detect visible light nucleic acids associated with womens hormones and specific diseases. These tools enable at-home analysis without professional intervention.
- Headquarters Minato, Japan
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website crane-bio.com
- Social LinkedIn
- Total Equity Funding$1.67M (USD)
in 1 rounds
- Latest Funding Round$1.67M (USD), Series A
Oct 2023
- InvestorsAxil Capital
& 2 more
Funding Insights of Cranebio
Cranebio has successfully raised a total of $1.67M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.67 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.67M
- Total Rounds 1
- Last Round Series A β $1.67M
- First Round $1.67M
(Oct 2023)
- Investors Count 3
All 1 funding rounds of Cranebio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $1.67M | Series A | β | β |
3 investors in total: 3 institutional.
Investors in Cranebio
Cranebio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Axil Capital, Nippon Venture Capital and Akigin Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| axilcapital.com | ||||
| nvcc.co.jp | ||||
| akigin-c-p.co.jp |
Investor details for Cranebio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cranebio
1 people are tracked at Cranebio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Daisuke Yamamoto | CEO | Leadership |
Complete people profiles for Cranebio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cranebio
2 dated milestones of Cranebio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Cranebio is founded.
- Funding First funding round of $1.7M.
Competitors of Cranebio
Cranebio has 2 listed competitors in our database, 1 of them funded. They include Miltel and MyCode.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mirtel.co.jp | 2012 | Hiroshima, Japan | $5.28M | Telomere tests for aging detection and cellular senescence are provided. | ||
| mycode.jp | 2014 | Tokyo, Japan | Provides reliable genetic testing services for personalized health insights. |
Detailed competitors of Cranebio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cranebio
The website of Cranebio (crane-bio.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 21.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cranebio
Complete news archive for Cranebio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cranebio
Cranebio was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Cranebio is headquartered in Minato, Japan. It is registered at Minato, Tokyo, Japan.
Daisuke Yamamoto is the CEO of Cranebio, as recorded in our data.
Cranebio is a funded company, having raised a total of $1.67M across 1 funding round to date. The company's 1st funding round was a Series A of $1.67M, raised on Oct 2023.
Cranebio was founded in 2021 and is based in Minato, Japan. Operations focus on the biotechnology sector, where self-service genetic test kits for womens health are developed. A wearable testing device and a next-generation rapid kit utilizing DNA origami technology are offered to detect visible light nucleic acids associated with womens hormones and specific diseases. These tools enable at-home analysis without professional intervention.
Cranebio has 3 investors. Key investors include Axil Capital, Nippon Venture Capital, and Akigin Capital Partners.